Safety Study of Thioridazine in Combination With Cytarabine to Treat Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia Clinical Trial

— THORIDAL  

Official title:

A Phase I Trial Evaluating Oral Thioridazine in Combination With Intermediate Dose Cytarabine in Patients 55 Years and Older With Acute Myeloid Leukemia Who Have Relapsed or Have Refractory Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02096289
• Other study ID #: OCOG-2013-THORIDAL
• Status: Completed
• Phase: Phase 1
• First received: March 20, 2014
• Last updated: December 6, 2016
• Start date: July 2014
• Est. completion date: September 2016

Study information

• Verified date: December 2016
• Source: Ontario Clinical Oncology Group (OCOG)
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

This is a Phase I trial investigating the safety of using thioridazine in addition to cytarabine in elderly patients with relapsed or refractory Acute Myeloid Leukemia.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 13
• Est. completion date: September 2016
• Est. primary completion date: August 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 55 Years to 80 Years

Eligibility

Inclusion Criteria:

• Have a diagnosis of AML according to the WHO Classification1

• AML is refractory or relapsed (requiring at least 5% leukemic blasts in the bone marrow, regardless of the presence of other features such as new or recurrent dysplastic changes or extra medullary disease) according to the following definitions:

• Relapsed (defined as = 5% leukemic blasts in the bone marrow) after three months from receiving up to three prior induction regimens.

• Refractory (defined as = 5% leukemic blasts in the bone marrow) to not more than one prior induction regimen (defined as failure to achieve a CR or CRi following induction therapy).

• 55 years of age or older.

Exclusion Criteria:

• Receiving any other systemic anti-leukemic therapy (standard or investigational).

• Having received more than two prior chemotherapy lines for AML. Induction/consolidation therapy and bone marrow transplant are each considered a line of therapy.

• Having received previous AML therapy within four weeks of the first dose of study drug, with the exception of hydroxyurea.

• Clinical evidence suggestive of CNS involvement with leukemia unless a lumbar puncture confirms the absence of leukemic blasts in the CSF.

• Acute promyelocytic leukemia.

• An ECOG performance status of 3 or more.

• Inadequate renal function (i.e., estimated GFR < 60 mL/min/1.73m2).

• Inadequate hepatic function (i.e., serum bilirubin > 1.5×ULN; AST, ALT and alkaline phosphatase > 2.5×ULN).

• Presence of acute or chronic GVHD.

• Presence of a systemic fungal, bacterial, viral or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment).

• Having any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver or other organ system that may place the patient at undue risk to undergo induction therapy.

• Diagnosed with a condition that can prolong the QT interval (e.g., long QT syndrome) or have a QTc interval = 470ms if male, or = 480ms if female.

• Left ventricular ejection fraction less than 45%.

• History of uncontrolled cardiac arrhythmia.

• Known severe hypotensive or hypertensive heart disease.

• Prior malignancy, unless the patient has been disease-free for at least five years following curative intent therapy, with the following exceptions: Patients with treated non-melanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia, regardless of the disease-free duration, if definitive treatment for the condition has been completed; or patients with organ-confined prostate cancer with no evidence of recurrent or progressive disease based on prostate-specific antigen (PSA) values if hormonal therapy has been initiated or a radical prostatectomy has been performed.

• Known HIV positivity.

• Known pregnancy or lactating female.

• Presence of a psychiatric disorder that would interfere with consent, study participation, or follow-up.

• Unable to provide informed consent.

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Acute Myeloid Leukemia
• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute

Intervention

Drug:
• Thioridazine

Locations

Country	Name	City	State
Canada	Juravinski Hospital & Cancer Centre	Hamilton	Ontario

Sponsors (3)

Lead Sponsor	Collaborator
Ontario Clinical Oncology Group (OCOG)	Hamilton Health Sciences Corporation, Juravinski Cancer Centre Foundation

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety	Both acute and late toxicities will be determined according to NCI-CTCAE version 4.03	Up to 36 days	Yes
Secondary	Assessment of Functional Leukemia Stem Cells	Bone marrow and peripheral blood samples obtained from patients treated with thioridazine and cytarabine will be analyzed in four separate assays.	Up to 36 days	No
Secondary	Pharmacokinetic Analysis of Thioridazine Serum Trough Levels	Pharmacokinetic modeling will be performed to estimate values for individual C min levels.	Up to 36 days	No
Secondary	Assessment of Objective Tumor Response	Tumor responses are categorized as either a complete remission, a complete remission with incomplete count recovery, a partial remission, a treatment failure, or as not evaluable	Up to 36 days	No
Secondary	Pharmacogenetic Analysis of Thioridazine Serum Trough Levels	Cytochrome P450 2D6 genotype will be determined to examine genetic contribution to thioridazine Cmin levels.	Up to 36 days	No